Occult hepatitis C virus infection in hemodialysis patients who achieved a sustained virological response to directly acting antiviral drugs: is it a concern?

被引:3
|
作者
Naguib, Hend [1 ]
Abouelnaga, Shady Fouad [2 ]
Elsayed, Mohamed Mamdouh [3 ]
机构
[1] Alexandria Univ, Fac Med, Hepatol & Internal Med Dept, Alexandria, Egypt
[2] Alexandria Univ Hosp, Clin & Chem Pathol Dept, Alexandria, Egypt
[3] Alexandria Univ, Fac Med, Nephrol & Internal Med Dept, Alexandria, Egypt
关键词
Direct-acting antiviral drugs; Hemodialysis; Occult hepatitis C infection (OCI); End-stage renal disease (ESRD); Sustained virological response (SVR); PREVALENCE;
D O I
10.1007/s11255-023-03621-1
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
PurposeHepatitis C virus infection is a major health problem in hemodialysis patients. Occult HCV infection is defined as the presence of HCV-RNA in hepatocytes or peripheral blood mononuclear cells without the detection of HCV-RNA in the serum. We aimed to evaluate the prevalence and predictors of occult HCV infection among hemodialysis patients after treatment with direct-acting antiviral agents.MethodsThis research is a cross-sectional study that included 60 HCV patients maintained on regular HD patients who achieved 24 weeks of sustained virological response after treatment with direct-acting antiviral agents. Real-time PCR was performed to detect HCV-RNA in peripheral blood mononuclear cells.ResultsHCV-RNA was detected in peripheral blood mononuclear cells of three patients (5%). Occult HCV infection cases were treated by Interferon/ribavirin before direct-acting antiviral agents and two of them had raised pre-treatment alanine aminotransferase levels. Logistic regression analyses revealed that high pre-treatment viral load and raised pre-treatment alanine aminotransferase were associated with an increased risk of occult HCV infection with p value of 0.041 and 0.029, respectively.ConclusionsOccult HCV infection in hemodialysis patients who achieved sustained virological response after treatment with direct-acting antiviral agents may occur, and this may necessitate dual testing for HCV in both serum and peripheral blood mononuclear cells to ensure viral clearance.
引用
收藏
页码:217 / 222
页数:6
相关论文
共 50 条
  • [1] Occult hepatitis C virus infection in hemodialysis patients who achieved a sustained virological response to directly acting antiviral drugs: is it a concern?
    Hend Naguib
    Shady Fouad Abouelnaga
    Mohamed Mamdouh Elsayed
    International Urology and Nephrology, 2024, 56 : 217 - 222
  • [2] DETECTION OF OCCULT HEPATITIS C VIRUS INFECTION IN EGYPTIAN PATIENTS WHO ACHIEVED A SUSTAINED VIROLOGIC RESPONSE TO DIRECT-ACTING ANTIVIRAL AGENTS
    Mashaal, Ahmed R.
    Abd El-Hameed, Mohamed
    El Ray, Ahmed A.
    Shemis, Mohamed A.
    Seyam, Moataz
    HEPATOLOGY, 2019, 70 : 921A - 921A
  • [3] Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response
    Tada, Toshifumi
    Kumada, Takashi
    Toyoda, Hidenori
    Mizuno, Kazuyuki
    Sone, Yasuhiro
    Kataoka, Saki
    Hashinokuchi, Shinichi
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 (12) : 1982 - 1988
  • [4] Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response
    Kobayashi, Natsuko
    Iijima, Hiroko
    Tada, Toshifumi
    Kumada, Takashi
    Yoshida, Masahiro
    Aoki, Tomoko
    Nishimura, Takashi
    Nakano, Chikage
    Takata, Ryo
    Yoh, Kazunori
    Ishii, Akio
    Takashima, Tomoyuki
    Sakai, Yoshiyuki
    Aizawa, Nobuhiro
    Nishikawa, Hiroki
    Ikeda, Naoto
    Iwata, Yoshinori
    Enomoto, Hirayuki
    Hirota, Seiichi
    Fujimoto, Jiro
    Nishiguchi, Shuhei
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2018, 30 (05) : 546 - 551
  • [5] Detection of Occult Hepatitis C Virus Infection in Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents for Recurrent Infection After Liver Transplantation
    Elmasry, Sandra
    Wadhwa, Sanya
    Bang, Bo-Ram
    Cook, Linda
    Chopra, Shefali
    Kanel, Gary
    Kim, Brian
    Harper, Tammy
    Feng, Zongdi
    Jerome, Keith R.
    Kahn, Jeffrey A.
    Saito, Takeshi
    GASTROENTEROLOGY, 2017, 152 (03) : 550 - +
  • [7] Association of liver stiffness and steatosis with hepatocellular carcinoma development in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response
    Tada, Toshifumi
    Nishimura, Takashi
    Matono, Tomomitsu
    Yoshida, Masahiro
    Yuri, Minako
    Fujiwara, Aoi
    Yuri, Yukihisa
    Takashima, Tomoyuki
    Aizawa, Nobuhiro
    Ikeda, Naoto
    Enomoto, Hirayuki
    Kumada, Takashi
    Iijima, Hiroko
    HEPATOLOGY RESEARCH, 2021, 51 (08) : 860 - 869
  • [8] Characteristics of hepatocellular carcinoma in patients with hepatitis C virus who received direct-acting antiviral therapy and achieved sustained virological response: The impact of a hepatologist on surveillance
    Tada, Toshifumi
    Kumada, Takashi
    Matono, Tomomitsu
    Nakamura, Shinichiro
    Sue, Masahiko
    Matsuo, Yu
    Takatani, Masahiro
    Iijima, Hiroko
    Tanaka, Junko
    JGH OPEN, 2022, 6 (07): : 462 - 469
  • [9] Hepatitis C late relapse in patients with directly acting antiviral-related sustained virological response at week 12
    Pisaturo, Mariantonietta
    Minichini, Carmine
    Starace, Mario
    Caroprese, Mara
    Macera, Margherita
    Brancaccio, Giuseppina
    De Pascalis, Stefania
    Santonicola, Antonella
    Lanza, Alfonso Galeota
    Zampino, Rosa
    Cotticelli, Gaetano
    Sagnelli, Evangelista
    Gaeta, Giovanni Battista
    Coppola, Nicola
    LIVER INTERNATIONAL, 2019, 39 (05) : 844 - 853
  • [10] RISK OF NON-HEPATOCELLULAR MALIGNANCIES IN PATIENTS WITH CHRONIC HEPATITIS C WHO ACHIEVED A SUSTAINED VIROLOGICAL RESPONSE WITH DIRECT-ACTING ANTIVIRAL THERAPY
    Miyase, Shiho
    Tsukano, Natsumi
    Kataoka, Aya
    Koga, Mutsuo
    Fujiyama, Shigetoshi
    HEPATOLOGY, 2019, 70 : 218A - 218A